<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_delavirdine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Delavirdine</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">04-23-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Delavirdine not currently available in Zambia. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar" name="INDICATIONS"></h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar" name="FORMS"></h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Rescriptor</I>
          </TD><TD valign="top">Delavirdine (DLV)</TD><TD valign="top">Pfizer</TD><TD>oral</TD><TD>tablet</TD><TD>200 mg</TD><TD>$316.35 per 180</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>tablet </TD><TD>100 mg </TD><TD>$0.88 </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar" name="USUAL ADULT DOSING"></h2>Pill burden: 6 tabs per day (200 mg tabs)<br>
<br>
<ul>
<li>400 mg PO tid with or without food (100mg tab should be dispersed in at least 3 oz of water before administration; 200mg tab is taken intact).</li>
<li>With <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: DLV 400mg tid + <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 600mg q8h (GI intolerance and high pill burden).</li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>: High rates of GI intolerance and high pill burden. No data with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> hgc; avoid use.</li>
<li>Not recommended with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>, APV, and <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>.</li>
<li>No data with DRV/r, TPV/r, <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> and <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>.</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar" name="RENAL DOSING"></h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>400 mg tid <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Usual dose. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Usual dose. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>No data. Usual dose likely; unlikely to be removed in dialysis due to high protein binding. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. Usual dose likely. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar" name="ADVERSE DRUG REACTIONS"></h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Rash in 18%; usually lasts 2 wks and does not require discontinuation unless desquamation or mucous membrane involvement; approximately 4% discontinue due to rash. High rates (70%) of cross-allergy between DLV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> [<A class="headLines" target="_new" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10928408&amp;dopt=abstract"><I>Ann Pharmacother</I> 2000;34: 940</A>].</li>
<li>Headache and fatigue (11-17%).</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Transaminase elevation in 2-5% of pts (less common and severe than with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>).</li>
<li>Nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Erythema multiforme or Stevens-Johnson syndrome. </li>
<li>Proteinuria.</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar" name="DRUG INTERACTIONS"></h2>CYP3A4 substrate and inhibitor. DLV may increase serum levels of other CYP3A4 substrates. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>
          </B></TD><TD valign="top">Clarithromycin AUC: increased by 100%; 14-hydroxy clarithromycin AUC: decreased by 75%;delavirdine AUC: increased by 44%</TD><TD valign="top">Dose adjustment recommended with impaired renal function. Cr clearance 30-60 mL/min: 50% of clarithromycin dose. Cr clearance &lt;30 mL/min: 25% of clarithromycin dose. Consider <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">azithromycin</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC: increased by 44% (compared to 800 mg q8h dose)</TD><TD valign="top">With co-administration, decrease indinavir to 600 mg q8h and use standard dose of DLV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>
          </B></TD><TD valign="top">Nelfinavir AUC: increased by 72%;delavirdine AUC: decreased by 42%; Cmin: decreased by 52%</TD><TD valign="top">Clinical significance unknown. Alternative PI should be considered.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">DLV AUC: decreased by 96%</TD><TD valign="top">Do not coadminister.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>
          </B></TD><TD valign="top">Saquinavir AUC: increased by 500%; DLV AUC: decreased by 15%</TD><TD valign="top">A beneficial interaction. No adjustment necessary. Use <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 800 mg tid + DLV 400 mg tid.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> (buffered)</B></TD><TD valign="top">DLV AUC: decreased by 20%</TD><TD valign="top">Consider <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> EC or administer DLV at least 1 hr prior to buffered <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> tabs/suspension.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Alprazolam
          </B></TD><TD valign="top">May Increase alprazolam serum levels</TD><TD valign="top">Contraindicated. Consider lorazepam, oxazepam, or temazepam with DLV co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">May significantly increase amiodarone serum levels</TD><TD valign="top">Use with caution. Data limited to case report of increased amiodarone levels with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> co-administration. Monitor for amiodarone ADR (PFTs and TSH). Consider monitoring serum levels of amiodarone. Long half-life may make titration difficult (consider alternative antiarrhythmics with cardiology consult).</TD>
</TR>
<TR>
<TD valign="top"><B>Amlodipine</B></TD><TD valign="top">May increase serum level of amlodipine</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV has the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Amphetamine</B></TD><TD valign="top">May increase amphetamine serum levels</TD><TD valign="top">Clinical significance unknown. Use with caution.</TD>
</TR>
<TR>
<TD valign="top"><B>Antacids</B></TD><TD valign="top">DLV AUC: decreased by 41%;decreased absorption of DLV</TD><TD valign="top">Clinically significant. Separate antacid dose by at least 1 hr before or 2 hrs after DLV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            APV
          </B></TD><TD valign="top">APV AUC: increased by 130%; DLV AUC: decreased by 61% and Cmin: decreased by 88% </TD><TD valign="top">Do not coadminister.</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum levels of artemether</TD><TD valign="top">Applies to all PIs and DLV: Close monitoring for artemether toxicity (bone marrow suppression, bradycardia and seizure).</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly Increase astemizole serum levels</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely</TD><TD valign="top">Applies to all PIs and NNRTIs: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum levels</TD><TD valign="top">Applies to all PIs and DLV: No data. The manufacturer of ATV, RTV, and APV does not recommend bepridil co-administration, this contraindication should extend to all PIs and DLV since a significant increase in bepridil serum levels can result in pro-arrhythmic events such as VT, PVC, and VFib.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">DLV levels may be decreased and carbamazepine levels may be increased.</TD><TD valign="top">Co-administration not recommended. Monitor carbamazepine levels and consider TDM of PIs and NNRTI. Consider alternative agents: valproic acid, lamotrigine, levetiracetam, or topiramate.</TD>
</TR>
<TR>
<TD valign="top"><B>Chlordiazepoxide</B></TD><TD valign="top">May increase serum levels of chlordiazepoxide</TD><TD valign="top">Applies to all PIs and DLV: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum levels.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum levels of clorazepate</TD><TD valign="top">Applies to all PIs and DLV: Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May increase serum levels of cyclophosphamide</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> resulting in a 50% increase in cyclophosphamide serum levels. Since all PIs and DLV have the potential of increasing cyclophosphamide levels, close monitoring of cyclophosphamide-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May increases serum levels cyclosporine</TD><TD valign="top">Monitor serum levels of cyclosporine closely with co-administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">May increase serum levels of diltiazem</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with diltiazem co-administration. Diltiazem should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels</TD><TD valign="top">Applies to all PIs and DLV: No data. Monitor disopyramide serum level (target: 2 to 7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum levels of docetaxel</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase serum levels of dofetilide</TD><TD valign="top">Applies to all PIs and DLV: No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea </B></TD><TD valign="top">May decrease DLV serum levels. Echinacea (400 mg 4xd) decreased CYP3A4 substrate (midazolam) by 23%.</TD><TD valign="top">Applies to all PIs and NNRTIs. Clinical significance unknown but should avoided until the safety of this combination is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot Alkaloids</B></TD><TD valign="top">May significantly increase serum levels of ergotamine resulting in acute ergot toxicity</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug interaction occurred with a CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>Estazolam</B></TD><TD valign="top">May increase serum levels of estazolam</TD><TD valign="top">Applies to all PIs and DLV: Consider an alternative benzodiazepines (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl Estradiol</B></TD><TD valign="top">Ethinyl estradiol levels decreased by 20%</TD><TD valign="top">Clinical significance unknown. Pts should be aware of potential interaction. Alternative birth control methods should be recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide</TD><TD valign="top">Applies to all PIs and DLV: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum levels of etoposide</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum levels of felodipine</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led PR interval prolongation). All PIs and DLV have the potential of prolonging PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Fentanyl</B></TD><TD valign="top">May significantly increase serum levels of fentanyl</TD><TD valign="top">Use with caution. Consider morphine.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and DLV: Avoid co-administration; if necessary, monitor flecainide trough level with co-administration. Target: 200-1000 ng/mL. Toxicity is frequent with trough serum levels above 1000 ng/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>Fluconazole </B></TD><TD valign="top">No interaction</TD><TD valign="top">Use standard doses of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Fluoxetine</B></TD><TD valign="top">DLV Cmin increased by 50%</TD><TD valign="top">Not significant. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum levels of flurazepam</TD><TD valign="top">Applies to all PIs and DLV: Consider an alternative benzodiazepines (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Food</B></TD><TD valign="top">DLV AUC was not affected by food</TD><TD valign="top">Administer DLV with or without food</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic supplement </B></TD><TD valign="top">No data </TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> resulting in <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> serum level reduction. No data with DLV. Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum levels of granisetron</TD><TD valign="top">Applies to all PIs and DLV: Consider an alternative benzodiazepines (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>H2-blocker</B></TD><TD valign="top">May decrease DLV absorption</TD><TD valign="top">Contraindicated.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interaction unlikely</TD><TD valign="top">Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May increase serum levels of ifosphamide</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Irinoteacan</B></TD><TD valign="top">May increase irinotecan serum levels</TD><TD valign="top">Applies to all PIs and DLV: Co-administration of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is contraindicated by manufacturer. All PIs and DLV also have the potential for significant interaction with irinotecan, therefore the co-administration should be done with extreme caution.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">DLV Cmin: increased by 50%</TD><TD valign="top">No clinical data; consider dose adjustment: DLV 200-400 mg tid.</TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine (systemic)</B></TD><TD valign="top">May increase lidocaine serum levels</TD><TD valign="top">No data. Use with caution, monitor lidocaine serum levels (target: 1.5 to 6 mcg/mL) with coadministration.</TD>
</TR>
<TR>
<TD valign="top"><B>Lovastatin</B></TD><TD valign="top">May significantly increase lovastatin levels</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, or fluvastatin (and possibly atorvastatin - start at 10 mg/d). Monitor for adverse effect due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>LPV</B></TD><TD valign="top">May increase LPV serum levels</TD><TD valign="top">Unlikely to be significant. Use standard dose for both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Mefloquine
          </B></TD><TD valign="top">May increase serum levels of mefloquine</TD><TD valign="top">Applies to all PIs and DLV: Monitor mefloquine levels. Monitor for mefloquine toxicity (dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>Methadone</B></TD><TD valign="top">DLV AUC not affected by methadone. Methadone PK was not evaluated but DLV may have the potential for increasing methadone serum levels.</TD><TD valign="top">Use standard DLV dose. Monitor for sedation; methadone dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and DLV: No data. Use with caution. Monitor EKG and serum levels. Serum levels exceeding 1.5 to 2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>Midazolam</B></TD><TD valign="top">May significantly increase midazolam levels</TD><TD valign="top">Single dose IV midazolam may be used; chronic midazolam administration (oral or intravenous) should be avoided. Consider alternative benzodiazepines (lorazepam, temazepam, or oxazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle</B></TD><TD valign="top">No data </TD><TD valign="top">Data limited to an interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC unchanged; <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> Cmin decreased by 47%. Clinical significance unknown. Avoid co-administration with DLV.</TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum levels of mirtazapine</TD><TD valign="top">Applies to all PIs and DLV: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine.)</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with NVP.</TD><TD valign="top">Applies to all PIs and NNRTIs: No significant interaction observed with NVP. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum levels of nefazodone</TD><TD valign="top">Applies to all PIs and DLV: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine.)</TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum levels of nifedipine</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum levels of nisoldipine</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and DLV have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Paclitaxel</B></TD><TD valign="top">Case reports of increased paclitaxel serum levels</TD><TD valign="top">Data limited to case reports of severe toxicity associated with DLV co-administration with paclitaxel. Close monitoring of paclitaxel-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum levels of PCP</TD><TD valign="top">Avoid PCP with DLV co-administration. Avoid all illicit drug use for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">May decrease serum level of PIs and NNRTIs. PIs and NNRTIs may increase or decrease phenobarbital serum level</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider TDM of PIs and NNRTIs.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">DLV AUC: decreased by approx 90% (population PK)</TD><TD valign="top">Co-administration not recommended. Monitor phenytoin levels and adjust as indicated. Consider alternative agents: (i.e valproic acid, lamotrigine, levetiracetam, or topiramate).</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum levels resulting in QTc prolongation.</TD><TD valign="top">Contraindicated. Consider alternative: Olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>PPI (Omeprazole or pantoprazole)</B></TD><TD valign="top">May decrease DLV absorption</TD><TD valign="top">Co-administration is not recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May increase propafenone serum level</TD><TD valign="top">Use with caution. Serum levels are not routinely recommended due to the poor correlation with efficacy and toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">May increase quinidine levels</TD><TD valign="top">No data. Use with caution with close monitoring of EKG (QTc) and serum levels: Target: 2 to 5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">RFB AUC: increased by 100%;delavirdine AUC: decreased by 80%</TD><TD valign="top">Contraindicated.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">DLV serum levels may be significantly decreased.</TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Rosuvastatin</B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e erythromycin) did not affect rosuvastatin serum levels</TD><TD valign="top">Interaction unlikely, but close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>RTV</B></TD><TD valign="top">RTV AUC: increased by 61%; Cmin: increased by 55%. No difference in delavirdine PK parameters.</TD><TD valign="top">No dose adjustment necessary.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May increase sildenafil serum levels</TD><TD valign="top">Use with caution. Do not exceed 25 mg in 48 hrs.</TD>
</TR>
<TR>
<TD valign="top"><B>Simvastatin</B></TD><TD valign="top">May significantly increase simvastatin levels</TD><TD valign="top">Contraindicated. Consider: pravastatin, rosuvastatin or low dose atorvastatin (start with 10 mg/d).</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May increase serum levels of sirolimus</TD><TD valign="top">Dose sirolimus based on serum levels. A significantly reduction of sirolimus dose with DLV co-administration is highly likely.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">DLV clearance may be increased significantly</TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>, but St John's work likely to affect the metabolism of DLV. Do not coadminister.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">May increase serum levels of tacrolimus</TD><TD valign="top">Dose tacrolimus based on serum levels. A significantly reduction of tacrolimus dose with DLV co-administration is highly likely.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum levels of tadalafil.</TD><TD valign="top">Applies to all PIs and DLV: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum levels of tamoxifen</TD><TD valign="top">Applies to All PIs and DLV: No data. Close monitoring of tamoxifen-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum levels of teniposide</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of teniposide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May increase terfenadine levels</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> interactions are unlikely</TD><TD valign="top">Applies to PIs and NNRTIs: Interactions are unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Trazadone</B></TD><TD valign="top">May increase serum level of trazadone</TD><TD valign="top">Applies to all PIs and DLV: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum levels.</TD><TD valign="top">Contraindicated. Consider alternative benzodiazepines(temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">May significantly increase serum levels of vardenafil.</TD><TD valign="top">Applies to all PIs and DLV: Do not exceed vardenafil 2.5 mg in 72 hrs (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) or 2.5 mg in 24 hrs (with other PIs and DLV). Consider sildenafil due to more clinical data and less pronounced interaction. Avoid coadministration with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum levels of verapamil</TD><TD valign="top">Applies to all PIs and DLV: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led PR interval prolongation). All PIs and DLV have the potential of prolonging PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum levels of vinblastine</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of vinblastine induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum levels of vincristine</TD><TD valign="top">Applies to all PIs and DLV: No data. Close monitoring of vincristine- induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">May increase voriconazole AUC. Voriconazole may increase DLV AUC.</TD><TD valign="top">No data with DLV. Use with close monitoring.</TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin</B></TD><TD valign="top">May increase warfarin effects.</TD><TD valign="top">Other NNRTIs and PIs may also affect warfarin requirements. Monitor INR closely and adjust warfarin as indicated.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar" name="RESISTANCE"></h2>
<ul>
<li>K103N; Y181C, V106M; 188L, P236L: High-level resistance.</li>
<li>G190A, G190S, P225H, F227L: Sensitive or even hypersusceptible (but no clinical data).</li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar" name="PHARMACOLOGY"></h2>
<a name="N10D12"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Non-competitive inhibition of HIV DNA polymerase resulting in disruption of catalytic site of the enzyme.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Bioavailability 85%. Absorption highly dependent on gastric acidity.</li>
<li>Metabolism and Excretion: 
                Metabolized by CYP 3A4 to several hydroxylated metabolites, which undergo subsequent glucuronidation. Both unchanged drug and metabolites are excreted in the feces.</li>
<li>Protein Binding: 
                98-99%</li>
<li>Cmax, Cmin, and AUC: 
                Steady-state mean AUC=83 mcg hr/mL; Cmax=16 mcg/mL; Cmin=7 mcg/mL (400mg tid).</li>
<li>T1/2: 
                5.8 hrs</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>No data. Consider dose reduction in ESLD.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category C: Placental passage of 4-15% in late-term rodent studies. Teratogenic in rodent studies resulting in ventricular septal defects. Maternal toxicity, embryotoxicity and decreased pup survival seen with doses 5x the human dose. No data on carcinogenicity.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>Unknown breast milk excretion. Breast feeding is not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar" name="COMMENTS"></h2>
<ul>
<li>Pros: May still have activity with G190A, and G190S, P225H, F227L mutations, but little clinical data; increases drug levels of some PIs.</li>
<li>Cons: Low potency; less clinical data than for other NNRTIs; tid dosing.</li>
</ul>
<a name="N10D53"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Friedland GH, Pollard R, Griffith B, et al.;
		Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.;        
		J Acquir Immune Defic Syndr;
		1999; Vol. 
		21; pp. 
		281-92;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10428106&amp;dopt=abstract" target="_new">10428106</a>
<br>
<b>Comments:</b>Prospective randomized study comparing the following regimens: DLV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>; DLV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>; DLV + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>; and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> in naive pts (&lt;6 mos of therapy). Therapy with DLV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> showed only modest antiviral activity and CD4 benefit compared with 2-drug regimens. VL reduction was not significantly different between <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> compared to DLV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> or DLV + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>. This study is consistent with other studies showing only modest antiviral potency with DLV-containing regimens. <br>
<br>
</li>
<li>Para MF, Meehan P, Holden-Wiltse J, et al.;
		ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.;        
		Antimicrob Agents Chemother;
		1999; Vol. 
		43; pp. 
		1373-8;
		<br>ISSN:
	        	0066-4804;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10348755&amp;dopt=abstract" target="_new">10348755</a>
<br>
<b>Comments:</b>Phase I-II dose-finding study. DLV monotherapy decreased VL by only 0.87-1.08 log by wk 2 (less potent than <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> or <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>). Subjects developed rapid DLV resistance. <br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_delavirdine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
</html>
